Cell Therapy News/Articles, page-15055

"The FDA process is pretty well established from decades of evaluating many different types of treatments and therapies and devices. The problem is that MSB's treatment claims have been consistently watered down and changed while launching new phase 3 trials even though the phase 2 trial failed..."

Sensational.

While I some years ago saw the sense in no longer reading the inane dross posted by your co-respondent, I couldn't help noticing from your response that the lame "FDA-ate-MSB's-homework" line of excuse still gets trotted out year after year.

That's despite the claim after the last US federal election that, whereas the last administration was negligent in failing to doing so, the new government were going to bring about changes at the FDA that would cause the folk at the FDA to see the error of their ways when it came to MSB.

Two years later, and the dastardly FDA continues to refuse to come up to the standard expected of it by certain MSB shareholders.


As for MSB getting to the point of self-sustaining commercialisation, well....

.